tiprankstipranks
Trending News
More News >

Nanobiotix initiated with a Buy at Stifel

Stifel analyst Clemence Thiers initiated coverage of Nanobiotix with a Buy rating and EUR 16 price target, implying 304% potential upside to the current share price. NBTXR3, Nanobiotix’s lead asset, is an innovative radioenhancer designed to improve the effectiveness of radiotherapy by amplifying the radiation dose intratumorally, triggering both local and systemic responses, the analyst tells investors in a research note. The firm says the company has an innovative physical-based approach to cancer treatment, which is supported by collaborations with prestigious partners.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

1